Versant promotes Mary Haak-Frendscho to venture partner
U.S. venture capital firm Versant Ventures, which this week closed its sixth life sciences fund at $538 million, has appointed Mary Haak-Frendscho to the role of venture partner based in Toronto. Haak-Frendscho, who joined Versant in 2016 as CEO of Toronto incubator Blueline Bioscience, will support the firm's efforts to build a Canadian biotech portfolio in partnership with academics and entrepreneurs. Versant also appointed Lloyd Segal, formerly a managing partner at Canadian healthcare private equity firm Persistence Capital Partners, as a Montréal-based entrepreneur-in-residence.
5 January 2017•6 mins read
